SCHOTT Pharma AG & Co. KGaA (XETRA:1SXP) — Stock Price
SCHOTT Pharma AG & Co. KGaA (XETRA:1SXP) is currently trading at €25.00 EUR, up 1.42% today. Over the past 52 weeks, shares have ranged between €12.96 and €25.00. This page tracks SCHOTT Pharma AG & Co. KGaA's live share price on the XETRA exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 1SXP stock market capitalisation.
SCHOTT Pharma AG & Co. KGaA (1SXP) Stock Price Chart — Daily History & Trading Volume
The chart below tracks SCHOTT Pharma AG & Co. KGaA's daily closing share price and trading volume on the XETRA exchange over the past year, giving a clear view of recent price momentum and liquidity.
SCHOTT Pharma AG & Co. KGaA Income Statement — Revenue, Profit & Earnings by Year
SCHOTT Pharma AG & Co. KGaA's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | €957.09 Million | €898.60 Million | €821.14 Million | €648.67 Million | €584.23 Million |
| Cost of Revenue | €634.48 Million | €582.11 Million | €524.72 Million | €422.50 Million | €388.22 Million |
| Gross Profit | €322.61 Million | €316.49 Million | €296.43 Million | €226.17 Million | €196.01 Million |
| Research & Development | €24.25 Million | €26.82 Million | €23.53 Million | €22.29 Million | €23.58 Million |
| SG&A | €124.48 Million | €122.09 Million | €110.21 Million | €92.01 Million | €89.23 Million |
| Total Operating Expenses | €767.13 Million | €727.68 Million | €651.81 Million | €533.42 Million | €492.62 Million |
| Operating Income | €189.96 Million | €170.92 Million | €169.34 Million | €115.25 Million | €91.61 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €13.49 Million | €7.25 Million | €2.69 Million | €1.67 Million | €1.92 Million |
| Income Before Tax | €183.97 Million | €185.80 Million | €158.29 Million | €123.28 Million | €95.30 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €149.69 Million | €151.84 Million | €125.38 Million | €100.75 Million | €77.48 Million |
SCHOTT Pharma AG & Co. KGaA Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes SCHOTT Pharma AG & Co. KGaA's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | €1.44 Billion | €1.23 Billion | €1.20 Billion | €739.89 Million | €596.02 Million |
| Total Current Assets | €588.60 Million | €468.34 Million | €554.52 Million | €302.16 Million | €238.98 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €3.25 Million | €1.53 Million | €1.49 Million | — | — |
| Net Receivables | €174.89 Million | €165.49 Million | €146.43 Million | €117.62 Million | €99.52 Million |
| Inventory | €140.44 Million | €138.94 Million | €128.94 Million | €83.52 Million | €63.22 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | €29.35 Million | €29.49 Million | €30.95 Million | €29.33 Million | €28.39 Million |
| Total Liabilities | €650.00 Million | €539.65 Million | €487.46 Million | €320.48 Million | €280.36 Million |
| Total Current Liabilities | €435.48 Million | €351.15 Million | €323.02 Million | €244.21 Million | €209.86 Million |
| Long-term Debt | — | — | €0.00 | €0.00 | €0.00 |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | €790.41 Million | €690.43 Million | €707.28 Million | €417.96 Million | €314.52 Million |
| Retained Earnings | — | €36.95 Million | €681.91 Million | €448.90 Million | €361.52 Million |
SCHOTT Pharma AG & Co. KGaA Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how SCHOTT Pharma AG & Co. KGaA generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | €225.33 Million | €181.65 Million | €182.12 Million | €132.21 Million | €104.40 Million |
| Capital Expenditures | €145.30 Million | €175.52 Million | €152.69 Million | €98.63 Million | €85.31 Million |
| Free Cash Flow | €80.03 Million | €6.13 Million | €29.43 Million | €33.59 Million | €19.09 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | €22.59 Million | €18.88 Million | €11.46 Million | €39.82 Million | €44.04 Million |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | €64.98 Million | €51.85 Million | €55.36 Million | €36.44 Million | €33.73 Million |
| Change in Cash | €1.24 Million | €-1.15 Million | €-2.39 Million | €8.82 Million | €8.73 Million |
SCHOTT Pharma AG & Co. KGaA Earnings History — EPS Actual vs. Analyst Estimates
Track SCHOTT Pharma AG & Co. KGaA's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 13, 2026 | — | 0.23 | — |
| Feb 11, 2026 | 0.00 | 0.18 | -100.00% |
| Dec 11, 2025 | 0.22 | 0.24 | -8.33% |
| Aug 12, 2025 | 0.30 | 0.29 | +3.45% |
| May 14, 2025 | 0.26 | 0.24 | +8.33% |
| Feb 13, 2025 | 0.19 | 0.19 | +0.00% |
| Dec 12, 2024 | 0.22 | 0.24 | -9.84% |
| Aug 29, 2024 | 0.31 | 0.20 | +55.00% |